Philippe Moreau, MD, on the Implications of Daratumumab Maintenance for Newly Diagnosed Multiple Myeloma

Video

Moreau discussed the implications of the second part of the CASSIOPEIA trial at the 2021 ASCO Annual Meeting.

CancerNetwork spoke with Philippe Moreau, MD, of the University Hospital of Nantes, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, regarding implications from part 2 of the phase 3 CASSIOPEIA trial (NCT02541383), which investigated daratumumab (Darzalex) maintenance following bortezomib, thalidomide, and dexamethasone (VTd) for patients with newly diagnosed multiple myeloma.

Transcription:

The main takeaway is that daratumumab maintenance is able to improve outcomes following stem cell transplantation, [although] this is restricted to patients who are not exposed as part of frontline treatment with a quadruplet [regimen] including daratumumab. We definitely need a longer follow-up to look at progression-free survival 2 [PFS2] and overall survival. When we evaluated PFS2, we also showed that there is a clear separation of the curves that is now occurring with a follow-up of 3 years; we definitely need a longer follow-up. The best PFS2 curve is the one for patients who received daratumumab up front and daratumumab maintenance, as well.

Reference

Moreau P & Sonneveld P. Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2. J Clin Oncol. 2021;39(suppl 15):8004. doi:10.1200/JCO.2021.39.15_suppl.8004

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
A panel of 4 experts on multiple myeloma
Video 1 - 4 KOLs are featured in "Treating Patients Referred to Academic Centers for CAR T"
Video 1 - 4 KOLs are featured in "Identifying Potential Candidates for CAR T-Cell Therapy"
Beth Faiman, CNP, PhD, an expert on multiple myeloma
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Related Content